Long-acting buprenorphine with Jo Neale
Addiction Audio8 Jun 2023

Long-acting buprenorphine with Jo Neale

Professor Joanne Neale talks to Addiction Audio about her latest research into how people feel during the first 72 hours of having long-acting buprenorphine (Buvidal). Jo talks about the recent history of this medication and how it predated the COVID-19 pandemic and was then brought to attention because it meant that people did not have to attend a pharmacy on a daily basis. Jo also talks about how this can be positive for some people but isn't appropriate for everyone.

Jo discusses the gap in the literature around how people respond to long-acting buprenorphine when it is first administered. Jo presents data from the first wave of a longitudinal study examining people's experiences throughout the medication. The findings from this first set of data will be used to help people prepare for the effects and to know what to expect.

Jo discusses using an embodiment and embodied cognition approach when analysing the data. This was chosen because the researchers saw how the data quickly became complex.

"People had these positive and negative experiences at the same time simultaneously; sometimes they were positive physical effects, sometimes they were positive psychological effects, sometimes they were negative physical effects, sometimes they were negative psychological effects. And when we started to map this out, we could see that it was quite complicated and that everything was interacting. And that brought us round to thinking that the concept of embodiment and embodied cognition are quite helpful here because they help us understand how the mind and body interact."

Original article: How do patients feel during the first 72 h after initiating long-acting injectable buprenorphine? An embodied qualitative analysis by Joanne Neale and colleagues. Published in Addiction (2023)

Hosted on Acast. See acast.com/privacy for more information.

Episoder(125)

Cannabis potency and psychotic experiences with Lindsey Hines

Cannabis potency and psychotic experiences with Lindsey Hines

In this episode, Dr Rob Calder talks to Dr Lindsey Hines about her study using longitudinal data to examine links between cannabis use, cannabis potency and psychotic experiences. Dr Hines talks about...

6 Jun 202425min

Cannabis use in the US with Jonathan Caulkins

Cannabis use in the US with Jonathan Caulkins

In this episode Dr Elle Wadsworth talks to Professor Jonathan Caulkins about self-reported cannabis use in the US between 1979 and 2022 and how those trends compare with alcohol use over the same peri...

22 Mai 202422min

Integrated care vans with Kathleen Page

Integrated care vans with Kathleen Page

In this episode, Ben Scher talks to Dr Kathleen Page about her evaluation of an integrated care van that ran in Baltimore offering healthcare interventions and buprenorphine prescribing. Dr Page discu...

9 Mai 202426min

Smoking and abdominal obesity with Germán Carrasquilla

Smoking and abdominal obesity with Germán Carrasquilla

In this episode Rob Calder talks to Dr Germán Carrasquilla about his study assessing whether smoking cased increases in abdominal obesity or belly fat. They discuss the implications of this kind of fa...

2 Mai 202417min

Benzodiazepines and treatment with Adam Bakker, Michael Liebrenz and Alexander Smith

Benzodiazepines and treatment with Adam Bakker, Michael Liebrenz and Alexander Smith

In this episode Ben Scher talks to Dr Adam Bakker, Professor Michael Liebrenz and Dr Alexander Smith about their commentary in response to a previous paper by Domzaridou and colleages (2023). They dis...

25 Apr 202423min

Contingency management with Gabriela Khazanov, James, McKay and Richard Rawson

Contingency management with Gabriela Khazanov, James, McKay and Richard Rawson

In this episode, Ben Scher talks to Dr Gabriela Khazanov, Professor James McKay and Professor Richard Rawson. They discuss what contingency management is and how effective it can be in treatment setti...

17 Apr 202427min

Xylazine, heroin and drug markets with Caroline Copeland

Xylazine, heroin and drug markets with Caroline Copeland

In this episode Ben Scher talks to Dr Caroline Copeland about her work analysing drug death data to identify drug use trends, harms and to inform policy. Caroline talks about how xylazine first entere...

9 Apr 202420min

Synthetic opioid production in Europe with Paul Griffiths

Synthetic opioid production in Europe with Paul Griffiths

In this episode, Dr Elle Wadsworth talks to Paul Griffiths about synthetic drug production in Europe including the differences between lab-made substances and diverted medical drugs. They discuss orga...

4 Apr 202433min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
jss
rekommandert
forskningno
sinnsyn
tomprat-med-gunnar-tjomlid
villmarksliv
rss-paradigmepodden
rss-nysgjerrige-norge
liberal-halvtime
nevropodden
fjellsportpodden
kvinnehelsepodden
diagnose
tidlose-historier
rss-inn-til-kjernen-med-sunniva-rose
psykopoden
nordnorsk-historie
rss-hoyt-lavt-med-ida-tonseth